INTELLION
Dead / Abandoned — Abandoned — no statement of use filed (as of 18 Nov 2024)
What this means for you
This application is over — abandoned 18 Nov 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97164075
- Mark type
- Stylized text
- Filed
- 09 Dec 2021
- Published for opposition
- 25 Oct 2022
- Abandoned
- 18 Nov 2024
- Attorney of record
- Rosaleen H. Chou
Goods and services
- Class 042 — Scientific and technological services: Software-as-a-Service (SaaS) services featuring non-downloadable computer software and Platform-as-a-Service (PaaS) non-downloadable computer software services featuring computer software platforms in the nature of non-downloadable computer software, non-downloadable computer applications, and web-based software, all for accessing cloud-based servers and remote client servers for measuring pre and post-surgical cancer, medical, and disease burden scores through bioinformatics and artificial intelligence, analyzing, testing, tracking, and reporting genetic patterns post-pre- and surgery, providing cancer, medical, and disease treatment recommendation, providing high precision personalized cancer, medical, and disease treatment monitoring throughout the patient cancer, medical, and disease encounter, reducing cancer, medical, and disease treatment costs, and accelerated cancer, medical, and disease drug development for use by pharmaceutical companies and laboratories, health systems, oncologists, physicians, cancer clinics, medical professionals, hospitals, and patients
- Class 044 — Medical, beauty and agricultural services: Genetic testing for medical purposes; medical diagnostic testing, monitoring and reporting services; medical testing and diagnostic services, namely, diagnostic testing, monitoring, tracking, and reporting for detecting minimal residual disease (MRD) by analyzing, testing, tracking, and reporting DNA, genomes, genotype, and genetic mutations using whole genome pattern recognition, low-input liquid blood biopsy, aggregated SNC and CNV signals, and tracking tumor progression as it evolves during the patient treatment and follow up period
Owner
- VERACYTE DIAGNOSTICS, LLC, New York, NY, US
- C2i Genomics, Inc., New York, NY, US
- C2i Genomics, Inc., New York, NY, US
Prosecution history
- 18 Nov 2024 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 18 Nov 2024 — ABANDONMENT - NO USE STATEMENT FILED
- 06 Aug 2024 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 06 Aug 2024 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 06 Aug 2024 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 06 Aug 2024 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 06 Aug 2024 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 11 Jul 2024 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 08 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Mar 2024 — SOU EXTENSION 2 GRANTED
- 07 Mar 2024 — SOU EXTENSION 2 FILED
- 07 Mar 2024 — SOU TEAS EXTENSION RECEIVED
- 11 Oct 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Oct 2023 — SOU EXTENSION 1 GRANTED
- 09 Oct 2023 — SOU EXTENSION 1 FILED